Lifecore Biomedical, Inc. (LFCR) P/E Ratio History
Historical price-to-earnings valuation from 2004 to 2025
Loading P/E history...
LFCR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Lifecore Biomedical, Inc. (LFCR) trades at a price-to-earnings ratio of -3.8x, with a stock price of $4.77 and trailing twelve-month earnings per share of $-0.91.
The current P/E is 104% below its 5-year average of 101.3x. Over the past five years, LFCR's P/E has ranged from a low of 14.2x to a high of 1458.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, LFCR trades at a 117% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, LFCR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LFCR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LFCR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $930M | 147.8 | - | +107%Best | |
| $8B | 25.5Lowest | 1.11Best | -25% | |
| $17B | 30.5 | - | -25% | |
| $12B | 29.8 | - | +1% | |
| $4B | 29.3 | - | +5% | |
| $3B | 4186.1 | - | +101% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
LFCR Historical P/E Data (2004–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Sun Aug 25 2024 00:00:00 GM | $6.00 | $0.06 | 100.0x | +95% |
| FY2024 Q4 | Sun May 26 2024 00:00:00 GM | $5.62 | $0.24 | 23.4x | -54% |
| FY2019 Q4 | Fri May 31 2019 00:00:00 GM | $9.92 | $0.01 | 1458.8x | +2746% |
| FY2019 Q3 | $12.84 | $0.24 | 54.5x | +6% | |
| FY2019 Q2 | Fri Nov 30 2018 00:00:00 GM | $15.41 | $0.79 | 19.6x | -62% |
| FY2019 Q1 | Fri Aug 31 2018 00:00:00 GM | $13.45 | $0.82 | 16.3x | -68% |
| FY2018 Q4 | $14.10 | $0.90 | 15.7x | -69% | |
| FY2018 Q3 | Wed Feb 28 2018 00:00:00 GM | $13.00 | $0.76 | 17.0x | -67% |
| FY2018 Q2 | $12.50 | $0.31 | 39.7x | -23% | |
| FY2018 Q1 | $13.00 | $0.35 | 37.6x | -27% | |
| FY2017 Q4 | Wed May 31 2017 00:00:00 GM | $14.00 | $0.39 | 36.1x | -30% |
| FY2017 Q3 | $12.60 | $0.47 | 26.9x | -48% |
Average P/E for displayed period: 51.3x
See LFCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LFCR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LFCR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLFCR — Frequently Asked Questions
Quick answers to the most common questions about buying LFCR stock.
Is LFCR stock overvalued or undervalued?
LFCR trades at -3.8x P/E, below its 5-year average of 101.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does LFCR's valuation compare to peers?
Lifecore Biomedical, Inc. P/E of -3.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is LFCR's PEG ratio?
LFCR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2004-2025.